FAIRFIELD, Conn., July 29, 2011 (GLOBE NEWSWIRE) -- Competitive Technologies, Inc. (OTCQX:CTTC) today announced that the Journal of Pain and Symptom Management recently published a new study involving the Calmare® Pain Therapy medical device featuring Scrambler Therapy™. The article, "Scrambler Therapy May Relieve Chronic Neuropathic Pain More Effectively Than Guideline-Based Drug Management: Results of a Pilot, Randomized, Controlled Trial," by Giuseppe Marineo, PhD, Vittorio Iorno, MD, Cristiano Gandini, MD, Vincenzo Moschini, MD, and Thomas J. Smith, MD, was published online July 15, 2011 at http://www.jpsmjournal.com/inpress. It will be available in hard copy later this year.
"We are pleased to report this new study which shows the Calmare Scrambler to effectively treat chronic neuropathic pain better than established drug protocols," said Aris Despo, CTTC's Executive Vice President. "Studies like this provide us with added incentive to move the Calmare Scrambler device into the pain management marketplace to help those suffering from chronic neuropathic pain find pain relief and regain a sense of normalcy in their lives."
About Competitive Technologies, Inc
Competitive Technologies is a global leader in developing and commercializing innovative products and technologies. CTTC is multifaceted, providing distribution, patent and technology transfer, sales and licensing services. CTTC's staff is focused on the needs of customers and matching those requirements with commercially viable products or technology solutions.
CTTC is the licensed worldwide distributor of the non-invasive Calmare® pain therapy medical device, which incorporates the biophysical "Scrambler Therapy™" technology developed in Italy by CTTC's client, Professor Giuseppe Marineo to treat neuropathic pain, including cancer pain. The Calmare® device is currently being manufactured for sale by CTTC's partner, GEOMC Co., Ltd. of Seoul, Korea. For more information on the device, visit www.calmarett.com. Visit CTTC's website: www.competitivetech.net.
Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2010, filed with the SEC on October 27, 2010, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.